Bli medlem
Bli medlem

Du är här


Medivir: Redeye initiates coverage of Medivir

We are initiating coverage of Medivir with a base case fair value of
SEK 29. With an experienced management team, a deep clinical pipeline
and multiple catalysts over the next 12 months, the share offers
great potential for a significant rerating as the assets become

Read more and download the research update:

Start following companies at Redeye to receive the latest equity
research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment


Författare Cision

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.